Prostate Cancer Clinical Trials in Dallas, Texas

19 studies are recruiting for prostate cancer in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

  1. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer ov…

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Parkland Health & Hospital System ( Site 0069), Dallas, Texas
    Locations
    298 in total
    Run by
    Merck Sharp & Dohme LLC

    See if you can join NCT06925737 on ClinicalTrials.gov

  2. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

    The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

    Stage
    Phase 1
    Ages
    12 and older
    Site
    UT Southwest Simmons Cancer Center, Dallas, Texas
    Locations
    77 in total
    Run by
    PMV Pharmaceuticals, Inc

    See if you can join NCT04585750 on ClinicalTrials.gov

  3. Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy

    The aim for this study is to assess the diagnostic performance of 64Cu-SAR-bisPSMA PET to detect regional nodal metastases.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    Urology Clinics of North Texas, Dallas, Texas
    Locations
    34 in total
    Run by
    Clarity Pharmaceuticals Ltd

    See if you can join NCT06056830 on ClinicalTrials.gov

  4. Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX014 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 and older
    Site
    SCRI at Mary Crowley, Dallas, Texas
    Locations
    6 in total
    Run by
    Janux Therapeutics

    See if you can join NCT07545811 on ClinicalTrials.gov

  5. A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer

    Researchers conducting this study hope to learn about the safety and effectiveness of combining two study drugs, relacorilant and enzalutamide, plus androgen deprivation therapy (ADT), also known as hormone therapy. This study is for individuals who have been diagnosed with advanced, high-risk pros…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    4 in total
    Run by
    University of Chicago

    See if you can join NCT05726292 on ClinicalTrials.gov

  6. DESTINY-PANTUMOUR04

    This study will evaluate the effectiveness of T-DXd in patients with HER2-positive (IHC 3+) locally advanced, unresectable, or metastatic solid tumors who have received prior systemic treatment for metastatic or advanced disease and have no satisfactory alternative treatment options in a real-world…

    Stage
    Not phased
    Ages
    18 to 130
    Site
    Research Site, Dallas, Texas
    Locations
    18 in total
    Run by
    AstraZeneca

    See if you can join NCT07124000 on ClinicalTrials.gov

  7. A Phase 1b/2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC

    This is a dose-finding study to assess the safety and preliminary antitumor activity of Pocenbrodib alone or with darolutamide in patients with metastatic castration-resistant prostate cancer (mCRPC)

    Stage
    Phase 1
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    19 in total
    Run by
    Pathos AI, Inc.

    See if you can join NCT06785636 on ClinicalTrials.gov

  8. This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

    This study will explore whether a combination of the investigational drug mevrometostat (PF-06821497) and enzalutamide will work better than taking enzalutamide alone in participants with mCSPC who are ARPI naïve and have not yet received chemotherapy in the mCSPC setting.

    Stage
    Phase 3
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center - Simmons Cancer Center, Dallas, Texas
    Locations
    337 in total
    Run by
    Pfizer

    See if you can join NCT07028853 on ClinicalTrials.gov

  9. Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)

    This study is a first-in-human, Phase 1, open-label, multicenter study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and the preliminary efficacy of JANX007 in adults with metastatic castration-resistant prostate cancer (mCRPC).

    Stage
    Phase 1
    Ages
    18 to 100
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    36 in total
    Run by
    Janux Therapeutics

    See if you can join NCT05519449 on ClinicalTrials.gov

  10. Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)

    This Phase II, single arm study evaluates a PSA-response-adapted approach to salvage radiotherapy after radical prostatectomy for prostate cancer. All participants will receive hypo-fractionated stereotactic radiotherapy to the prostate fossa. At 5 weeks, biochemical response will be assessed. resp…

    Stage
    Phase 2
    Ages
    18 and older
    Site
    UT Southwestern Medical Center-Dallas, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT07313241 on ClinicalTrials.gov

  11. Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance

    This is a prospective study to determine if the use of curcumin randomized against placebo will reduce cancer progression in patients with prostate cancer undergoing active surveillance.

    Stage
    Phase 3
    Ages
    40 to 89
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT03769766 on ClinicalTrials.gov

  12. Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer

    The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as [177Lu]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as …

    Stage
    Phase 4
    Ages
    18 to 100
    Site
    Univ of Texas Southwest Med Center, Dallas, Texas
    Locations
    54 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT05803941 on ClinicalTrials.gov

  13. Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

    This is a Phase II/III study. Patient population is adult participants with PSMA-positive mCRPC who had treatments with androgen receptor pathway inhibitor (ARPI) and taxane-based chemotherapy and progressed on or after [177Lu]Lu-PSMA targeted therapy. Treatment of interest: the investigational tre…

    Stage
    Phase 2
    Ages
    18 to 100
    Site
    Texas Oncology, Dallas, Texas
    Locations
    81 in total
    Run by
    Novartis Pharmaceuticals

    See if you can join NCT06780670 on ClinicalTrials.gov

  14. Outcomes of Focal Ablation for Prostate Cancer

    This study will be designed to define the efficacy and safety of ablative therapies in the management of localized prostate cancer and comprehensively evaluate quality of life outcomes and oncologic control following treatment.

    Stage
    Not phased
    Ages
    18 to 90
    Site
    UTSW, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT05478694 on ClinicalTrials.gov

  15. Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy

    This is a prospective study to determine if the adjuvant use of Curcumin improves recurrence-free survival.

    Stage
    Phase 3
    Ages
    30 to 80
    Site
    UT Southwestern Medical Center, Dallas, Texas
    Run by
    yair lotan

    See if you can join NCT02064673 on ClinicalTrials.gov

  16. A Study of CLSP-1025 in Adult Patients With Solid Tumors That Harbor the p53 R175H Mutation

    Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Mary Crowley Cancer Research, Dallas, Texas
    Locations
    21 in total
    Run by
    Clasp Therapeutics, Inc.

    See if you can join NCT06778863 on ClinicalTrials.gov

  17. A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate Cancer

    Medicines that reduce the amount of testosterone in the body are commonly used to treat prostate cancer. PRL-02 depot is a potential treatment for men with advanced prostate cancer. It is given by an injection into the muscle. Men with advanced prostate cancer can take part in this study. Their can…

    Stage
    Phase 1
    Ages
    18 and older
    Site
    Urology Clinics of North Texas, Dallas, Texas
    Locations
    25 in total
    Run by
    Astellas Pharma Global Development, Inc.

    See if you can join NCT04729114 on ClinicalTrials.gov

  18. Non-significant Risk (NSR) Study of [68Ga]-PSMA-11 (Illuccix) as a BgRT BioGuide on RefleXion X1

    To qualitatively determine the imaging performance of PET-CT imaging subsystem of the RefleXion X1 System Device in patients undergoing standard-of-care (SOC) [68Ga]-PSMA-11 PET-CT using Illuccix on the same day.

    Stage
    Not phased
    Ages
    Any age
    Site
    Ut Southwestern Medical Center, Dallas, Texas
    Run by
    University of Texas Southwestern Medical Center

    See if you can join NCT06353321 on ClinicalTrials.gov

  19. Customized TULSA-PRO Ablation Registry

    This patient registry will capture data from patients who have been or who are undergoing the transurethral ultrasound ablation (TULSA) procedure as part of their routine clinical care. The registry will shed light on real-world outcomes of safety and efficacy of the procedure and understand how a …

    Stage
    Not phased
    Ages
    18 and older
    Site
    University of Texas Southwestern Medical Center, Dallas, Texas
    Locations
    5 in total
    Run by
    Profound Medical Inc.

    See if you can join NCT05001477 on ClinicalTrials.gov

How to read this page. Every study here comes from ClinicalTrials.gov, the public registry that research teams are required to file with. We have summarised each one in plain language and shown where it is running. We have not changed what any study says it is doing.

What TrialBoost is. We help people find research that might suit them, and, if they ask us to, we pass their details to the research team running it. We are not a doctor, a research site, or a study sponsor, and we do not decide who takes part in anything. Joining costs nothing and you can change your mind at any point.

Paid placement. Some studies pay us when someone asks to be connected to them. Those are labelled Sponsored wherever they appear, and they only appear when they match what you were actually looking for.